

26 August 2016

Company Update

Antisense Therapeutics Limited (“ANP” or “the Company”) wishes to advise that the Board has recently met to assess the progress of current partnering and non-dilutive funding initiatives along with a number of strategic options including potential new growth opportunities to complement the Company’s existing product pipeline, core expertise and to leverage its balance sheet.

Mark Diamond, Managing Director and CEO of Antisense Therapeutics along with other Company representatives will be in the US next month to follow up on a number of related business development initiatives and leads currently being progressed. Following these interactions, the Company will also attend the BioPharm America 2016 <http://www.biopharminsight.com/events/biopharm-america-2016> international partnering conference, where further meetings will be held with a number of pharmaceutical companies.

ANP will update shareholders on the material progress of specific strategic initiatives.

Contact Information: Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (0)3 9827 8999

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Ionis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-I levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.